Search Results

Foreign currency Share based Contributed Equity translation reserve payment reserve Retained earnings Total Consolidated Entity US$m US$m US$m US$m US$m 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 As at the beginning of the year (4,603.0) (4,634.5) (5.7) 29.1 247.7 195.1 9,612.3 8,490.2 5,251.3 4,079.9 Profit for the period - - - - - - 2,102.5 1,918.7 2,102.5 1,918.7 Other comprehensive income - - 13.3 (34.8) - - (13.6) (67.1) (0.3) (101.9) Total comprehensive income for the full year 2,102.2 1,816.8 Transactions with owners in their capacity as owners Opening balance sheet adjustment adopting AASB 16 and 15 (See Accounting Policies disclosure) - - - - - - (65.0) 74.0 (65.0) 74.0 Share based payments - - - - 81.0 52.6 - - 81.0 52.6 Dividends - - - - - - (883.1) (806.8) (883.1) (806.8) Share issues - Employee share scheme 42.0 31.5 - - - - - 42.0 31.5 Other - - - - - - (0.8) 3.3 (0.8) 3.3 As at the end of the year (4,561.0) (4,603.0) 7.6 (5.7) 328.7 247.7 10,752.3 9,612.3 6,527.6 5,251.3

US$1.85 total full year dividend per share.

To determine the incidence and impact of influenza on the pediatric population in Italy and the associated healthcare utilization, researchers analyzed data from Pedianet, a pediatric primary-care database, over a 10-year period (2010-2011 through 2019-2020).

2020

The full year fixed reward for P Perreault was US$1,856,133, the full year cash STI payment was US$2,262,385 and the full year share based payment expense was US$3,654,625.

In 2020, CSL worked with the University of Queensland in the early stages of its UQ-CSL v451 COVID-19 vaccine candidate.

The approval of Vafseo for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months is based on efficacy and safety data from the INNO 2 VATE program and an assessment of post marketing safety data from Japan where Vafseo was launched in August 2020.

The indication of "Berinert® S.C. Injection 2000" was designated as an Orphan Drug on August 17, 2020, with the expected indication of "prevention of hereditary angioedema attacks".

Vitaeris was acquired in June 2020, expanding our transplant and community contributions.

CSL Chief Communications & Brand Officer talks to PRWeek about what work looks like these days – including the morning routine he sticks to even when working in other time zones.